Project Category : CNS and GI
LATEST INDUSTRY PROJECTS IN CNS AND GI
Mirapex (Pramipexole) - Treatment for Parkinson's Disease
Mirapex (Pramipexole) is a medication indicated for Parkinson's...
Mirapex (Pramipexole) is a medication indicated for Parkinson's...
Lurasidone - Treatment for Schizophrenia and Bipolar Disorder
Lurasidone is an atypical antipsychotic agent developed by Japan's...
Lurasidone is an atypical antipsychotic agent developed by Japan's...
Lamictal – Approved Treatment for Epilepsy and Bipolar
Lamictal XR (lamotrigine), developed by GlaxoSmithKline, is an...
Lamictal XR (lamotrigine), developed by GlaxoSmithKline, is an...
Dimebon - Investigational Compound Indicated for the Treatment of Alzheimer's and Huntington's disease
Dimebon (latrepirdine) is an investigational compound indicated...
Dimebon (latrepirdine) is an investigational compound indicated...
Zegerid – Proton Pump Inhibitor for Treatment of Heartburn
Zegerid is a proton pump inhibitor (PPI) comprising omeprazole,...
Zegerid is a proton pump inhibitor (PPI) comprising omeprazole,...
- Alemtuzumab – Potential in Multiple Sclerosis,
- Almorexant - Agent for Treatment of Sleep Disorders,
- Bifeprunox - Atypical Antipsychotic Drug,
- Caprospinol, Therapy for Alzheimer's Disease (AD),
- Cerovive - Neuroprotectant for the Treatment of Acute Ischaemic Stroke,
- Cilansetron - New Treatment for IBS,
- Dimebon - Investigational Compound Indicated for the Treatment of Alzheimer's and Huntington's disease,
- Fampridine-SR – Treatment for Multiple Sclerosis,
- Florbetaben - 18F-Radiolabelled Tracer For Diagnosis of Alzheimer's Disease,
- Gaboxadol - Investigational Agent for the Treatment of Sleep Disorders,
- HCT 3012 - COX-Inhibiting Nitric Oxide-Donator (CINOD) for Relief of Pain and Inflammation,
- Iloperidone - Atypical Antipsychotic for Schizophrenia,
- Iluvien Diabetic Macular Edema Treatment, USA
- Lamictal – Approved Treatment for Epilepsy and Bipolar, USA
- Lexapro – Treatment for Major Depressive Disorder in Adolescents,
- Licofelone - Novel Analgesic and Anti-Inflammatory Agent for Osteoarthritis,
- Lurasidone - Treatment for Schizophrenia and Bipolar Disorder, Japan
- LY2140023 – Treatment of Schizophrenia,
- Lyrica (Pregabalin) - New Gabapentinoid with Wide Clinical Application,
- M6G, A New Morphine Derivative For Post-Operative Pain Relief,
- Mirapex (Pramipexole) - Treatment for Parkinson's Disease, Germany
- Mylinax - Novel Therapy for the Treatment of Multiple Sclerosis,
- NG2-73 - A Novel Agent For The Treatment of Insomnia,
- Olcegepant - Novel Therapy for Acute Migraine,
- Osanetant - Novel Investigational Agent for the Treatment of Schizophrenia,
- Paxil – SSRI for the Treatment of Major Depressive Disorders, USA
- Phenserine - Next Generation AChE Inhibitor for Alzheimer's Disease (AD),
- Plectasin NZ2114 - Novel Microbial Agent,
- Prexige - COX-2 Inhibitor for the Relief of Pain and Inflammation,
- Rasagiline - Second-Generation MAO-B Inhibitor for the Treatment of Parkinson's Disease,
- Rember - Therapy for Alzheimer's Disease,
- Rezular – Oral Treatment for IBS,
- Sativex - Investigational Cannabis-Based Treatment for Pain and Multiple Sclerosis,
- Semagacestat – Gamma Secretase Inhibitor for Alzheimer's Disease (AD),
- TB-402 – Therapeutic Monoclonal Antibody for VTE AND AF,
- Treximet - Next-Generation Treatment for Migraine,
- Tysabri - Therapeutic Monoclonal Antibody (MAb) for the Treatment of Multiple Sclerosis,
- V1512 - Treatment of Parkinson's Disease,
- Vesicare - Oral Selective Muscarinic Receptor Antagonist for Overactive Bladder (OAB),
- Zegerid – Proton Pump Inhibitor for Treatment of Heartburn,
- Zyprexa – Antipsychotic for the Treatment of Schizophrenia, Psychotic and Bipolar Disorders,
